Conclusions
All patients with indication for AVR with a biological bioprosthesis
could potentially benefit from a shorter and easily reproducible
treatment. This seems to be especially beneficial in patients more
sensitive to ischemia, technically difficult procedures, patients with a
high risk of PPM, and patients who require faster recovery.
Our study further confirms the excellent clinical and hemodynamic
performance and safety of the Perceval ® valve, a
truly sutureless aortic prothesis, in a moderately large cohort of
patients, even up to the 5-year follow-up. Consistent with current
literature, the Perceval ® valve allowed reduced
aortic cross-clamping, CPB and surgical times due to its easy and rapid
implantation technique as well as low rates of mortality, complications,
or dysfunctions early and up to 5 years, even in our cohort of mostly
older patients with comorbidities. Additionally, it has been proven to
facilitate the reproducibility and resurgence of minimally invasive
approaches, reducing additional postoperative complications.